The BAS Booster has diverse applications that are not limited to any single therapeutic category. The only requirement for a drug to potentially benefit from the technology is that it is orally degraded by CYP 3A.

Dose-sparing regimens:
Co-administration or co-formulation with the BAS Boosters can be used to reduce the drug dose required to achieve therapeutic efficacy. Prominent drugs where the boosting principle with CYP 3A inhibitors has been successfully demonstrated include ketoconazole with the immunosuppressant cyclosporine in the treatment of transplant patients, and ritonavir with HIV protease inhibitors.

Improved compliance:
Use of the BAS Booster may result in the elimination or reduction of food effects, reduction in pill count or reduction in dosing frequency- all factors that would simplify a therapeutic regimen and enhance patient compliance.

Conversion of parenteral drugs to oral doses:
Certain drugs exhibiting pronounced degradation by CYP 3A are administered intravenously (IV) in order to avoid the first pass effect. In some cases re-formulation with the BAS Booster may be effective in enabling oral dosing. A class of drugs where conversion has been demonstrated with CYP 3A inhibitors is the taxanes (i.e., paclitaxel and docetaxel).
Oral dosing will generally be a much more cost effective therapy than IV because of the elimination of hospital and ancillary costs. It is a method of treatment normally preferred by the patient.

Resurrection of failed drug candidates:
There are no reliable methods for predicting the oral bioavailability of drugs in development. A major reason for candidate drugs failing to reach market is because of bioavailability issues encountered during development programs. Candidates degraded by CYP 3A may have their efficacy enhanced sufficiently by the use of the BAS Booster to make the difference in progressing to market. Rescuing drug candidates in this manner could recapture considerable sunk investment by pharmaceutical companies.

Extending patent life:
Re-formulation with the BAS Booster could be an effective strategy for extending the patent life of established drugs and for generating improvements in therapy attractive to physicians and patients that can be leveraged to compete with generic products.